Clinical Trial Update: Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Sinibolimab in combination with Lenvatinib as neoadjuvant therapy for locally advanced unresectable differentiated thyroid car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Sinibolimab (sinibolimab)

Snippet

Sponsor: Zhejiang University | Conditions: Differentiated Thyroid Carcinoma (DTC), Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING